Skip to main content
. 2022 Mar 1;22:224. doi: 10.1186/s12885-022-09302-z

Table 2.

Previous treatments received by patients in the study

Agent Type Number Treated
Alkylating Agent
 Temozolomide 20
 Cisplatin 8
 Oxaliplatin 6
Topoisomerase Inhibitor
 Irinotecan 9
Antimetabolite
 Capecitabine 24
DNA Synthesis Inhibitor
 Etoposide 12
m-TOR Inhibitor
 Everolimus 42
 Sirolimus 1
VEGF Inhibitor
 Sunitinib 6
PD-1 Inhibitor
 Pembrolizumab 4
 Nivolumab 4
CTLA-4 Blockade
 Ipilimumab 2